Olivier de Beaumont
Chief Tech/Sci/R&D Officer chez Stallergenes Greer, Inc.
Profil
Olivier de Beaumont is currently the Senior VP & Head-Global Clinical Development at Stallergenes Greer, Inc. He previously worked as the Senior Vice President-Global Medical Affairs at Stallergenes SA and as the Chief Medical Officer & Head-Regulatory Affairs at Valerio Therapeutics SA. Dr. de Beaumont holds an MBA degree from ESCP Europe.
Postes actifs de Olivier de Beaumont
| Sociétés | Poste | Début |
|---|---|---|
Stallergenes Greer, Inc.
 Stallergenes Greer, Inc. Pharmaceuticals: MajorHealth Technology Part of Stallergenes Greer Ltd., Stallergenes Greer, Inc. specializes in the development and commercialization of allergy immunotherapy products for use in the diagnosis and treatment of allergies. The private company is based in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/01/2005 |
Anciens postes connus de Olivier de Beaumont
| Sociétés | Poste | Fin |
|---|---|---|
| VALERIO THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01/09/2022 |
| STALLERGENES | Corporate Officer/Principal | - |
Formation de Olivier de Beaumont
| ESCP Europe | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VALERIO THERAPEUTICS | Health Technology |
| Entreprise privées | 2 |
|---|---|
Stallergenes SA
 Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Stallergenes Greer, Inc.
Stallergenes Greer, Inc. Pharmaceuticals: MajorHealth Technology Part of Stallergenes Greer Ltd., Stallergenes Greer, Inc. specializes in the development and commercialization of allergy immunotherapy products for use in the diagnosis and treatment of allergies. The private company is based in Cambridge, MA. | Health Technology |
